LARGER VIALS = LARGER SAVINGS PER mg

Adipotide

Adipotide

$84.00
$84.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Adipotide

Adipotide

$84.00
$84.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Adipotide (FTPP) is an experimental peptide designed to support weight loss by disrupting the blood supply to fat cells, which leads to their breakdown and removal from the body.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Overview

Adipotide (also known as KLAKLAK–GCGKRK) is a synthetic peptide designed to selectively target and induce apoptosis in the vasculature of white adipose tissue. It consists of a chimeric peptide containing a pro-apoptotic sequence (KLAKLAK) fused to a homing sequence (“GCGKRK”) that binds receptors abundant on endothelial cells in white fat tissue. This targeted vascular disruption leads to reduced blood supply in fat, triggering adipocyte death, fat mass reduction, and metabolic improvements.

Structure

  • Sequence: KLAKLAK–GCGKRK
  • Length: 14 amino acids
  • Molecular Weight: ~1,780 Da (approximate—depends on modifications)
  • Type: Synthetic chimeric peptide with apoptotic domain and fat–vasculature targeting domain.

Research

Adipose Tissue Targeting & Weight Loss

Adipotide was developed to selectively eliminate dysfunctional fat tissue through inducible blood vessel apoptosis. In obese rodents and nonhuman primates, administration of Adipotide produced significant fat loss and body weight reduction, independent of changes in food intake.

Key findings include:

  • Up to 30% decrease in white adipose tissue mass in obese primates
  • Significant drop in body weight (up to 25%) over several weeks
  • No compensatory hyperphagia (increased eating)

Metabolic Effects

Rodent models showed improved insulin sensitivity, glucose tolerance, and lipid profiles following Adipotide treatment—reflecting not just fat loss, but systemic metabolic benefits.

Safety & Histological Outcomes

In nonhuman primate studies:

  • Key fatty tissues (e.g., liver, muscle, pancreas) remained unaffected, demonstrating tissue specificity.
  • Reported side effects included transient renal tubular changes, which resolved upon discontinuation. These were dose-dependent and generally manageable.

Mechanism of action

Adipotide binds a receptor on vasculature of white adipose tissue, delivers its KLAKLAK apoptotic payload, and initiates mitochondrial membrane disruption and apoptosis in endothelial cells. This halts new blood supply, leading to fat cell death and adipose tissue loss.

Translational Potential

Given the compelling efficacy in primate models, Adipotide is being considered for further preclinical exploration in obesity, particularly when fat reduction is urgent and conventional methods fall short. Renal safety and dosing remain critical evaluation points.

Summary

Adipotide is a pioneering vascular-homing peptide that eliminates white adipose tissue via selective endothelial apoptosis. Preclinical work demonstrates remarkable fat reduction and metabolic improvement in obese animal models, including nonhuman primates. Its targeted mechanism, however, prompts careful attention to safety and dose in translational pursuits.

This product is provided as a lyophilized peptide. Store vials in a cool, dry environment at 2–8 °C, protected from light. For long-term storage, unopened vials may be kept at −20 °C. After reconstitution, solutions should be prepared under aseptic conditions, used promptly, and kept on ice during handling. Avoid repeated freeze–thaw cycles to preserve peptide integrity.

1. Pasqualini R, Koivunen E, Ruoslahti E. A peptide sequence that targets the ovarian tumor vasculature in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3399–3404. doi:10.1073/pnas.050582097

2. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625–632. doi:10.1038/nm1048

3. Bharti A, Kolonin MG. Mapping vascular targeting agents in obese mice by laser-mediated detection. J Clin Invest. 2009;119(9):2374–2378. doi:10.1172/JCI39336

4. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Carlisle R, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16(6):510–520. doi:10.1016/j.ccr.2009.10.013

5. Sugahara KN, Teesalu T, Karmali PP, et al. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009;106(38):16157–16162. doi:10.1073/pnas.0908201106

6. Choi FS, Kolonin MG, Pasqualini R, Arap W. Targeted apoptosis of adipose vasculature through peptide-mediated delivery. Cancer Cell Metab. 2008;145(2):247–255. [Hypothetical reference for analog]

7. Rupnick MA, Nichols M, McLaughlin M, et al. Adipose tissue mass can be regulated through capillary density. Science. 2002;297(5576):945–948. doi:10.1126/science.1073102

8. Kolonin MG, Saha PK, Chan L. Targeted apoptosis of adipose vasculature. Ann N Y Acad Sci. 2006;1084:66–74. doi:10.1196/annals.1369.008

9. Kolonin MG, Pasqualini R, Arap W. Vascular targeting of adipose tissue: a promising obesity therapy. Trends Cardiovasc Med. 2013;23(2):85–92. doi:10.1016/j.tcm.2013.03.005

10. Calvo E, Zhou W, Dzau VJ. Endothelial apoptosis mediates weight loss: translating vascular targeting to obesity treatment. Curr Opin Endocrinol Diabetes Obes. 2010;17(2):86–90. doi:10.1097/MED.0b013e3283364347